Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults
Public ClinicalTrials.gov record NCT05266456. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at 3 dose levels compared to PCV20 in adults aged 50 to 64 years of age in Phase 2.
Study identification
- NCT ID
- NCT05266456
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 835 participants
Conditions and interventions
Conditions
Interventions
- 24 valent pneumococcal conjugate vaccine Biological
- 20 valent pneumococcal conjugate vaccine Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 21, 2022
- Primary completion
- Jan 9, 2023
- Completion
- Jan 9, 2023
- Last update posted
- Apr 17, 2024
2022 – 2023
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CenExel RCA | Hollywood | Florida | 33024 | — |
| Precision Clinical Research | Sunrise | Florida | 33351 | — |
| Meridian Clinical Research | Savannah | Georgia | 31406 | — |
| Velocity Clinical Research | Valparaiso | Indiana | 46383 | — |
| Johnson County Clin-Trials | Lenexa | Kansas | 66219 | — |
| Benchmark Research | Metairie | Louisiana | 70006 | — |
| Alliance for Multispecialty Research | Kansas City | Missouri | 64114 | — |
| Rochester Clinical Research | Rochester | New York | 14609 | — |
| Acellacare of Wilmington | Wilmington | North Carolina | 28401 | — |
| Velocity Clinical Research | Warwick | Rhode Island | 02886 | — |
| Coastal Carolina Research | North Charleston | South Carolina | 29405 | — |
| Benchmark Research | San Angelo | Texas | 76904 | — |
| JBR Clinical Research | Salt Lake City | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05266456, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 17, 2024 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05266456 live on ClinicalTrials.gov.